This guidance provides recommendations for increasing enrollment of females in clinical trials, analyzing and interpreting sex-specific data, and including sex-specific information in regulatory submissions of medical products
Similar Posts
CDER and CBER accept first submission to ISTAND Pilot Program
FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have accepted the agency’s first submission into the Innovative Science and Technology Approaches for New Drugs (ISTAND) Pilot Program.Early Alert: Glucose Monitor Sensor Issue from Abbott Diabetes Care
Certain Abbott Diabetes Care Continuous Glucose Monitor sensors may provide incorrect low glucose readingsConcord Biotech Limited – 04/28/2025-05/02/2025
Concord Biotech Limited – 04/28/2025-05/02/2025. Country: India. Record Type: 483Products Claiming to “Cure” Cancer Are a Cruel Deception
Many ads on social media and “healthy” websites claim their products can cure cancer. They cannot.FDA Approves Labeling Changes that Include a Boxed Warning for Immune Effector Cell-associated Enterocolitis Following Treatment with Ciltacabtagene Autoleucel (CARVYKTI, Janssen Biotech, Inc.)
The FDA has received reports of immune effector cell-associated enterocolitis (IEC-EC) in patients who received treatment with CARVYKTI.Search for Regulatory References | Drugs
Find information on drug development, applications, submissions, manufacturing & quality, safety, labeling and more